FindTrial
Sign In

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Pre-Approval Access Single Patient Request Treatment for Talquetamab for Treating Physician Use in Relapsed or Refractory Multiple Myeloma

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05503550
Enrollment
Unknown
Registered
2022-08-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma

Brief summary

The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

Interventions

DRUGTalquetamab

Talquetamab will be administered subcutaneously (SC).

Sponsors

Janssen Research & Development, LLC
Lead SponsorINDUSTRY

Eligibility

Age
18 Years to No maximum

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026